NCT02688140 - Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

January 20, 2025

Study Completion Date

January 20, 2025

Conditions

Acute Promyelocytic Leukemia

Interventions

DRUG

Arsenic trioxide

DRUG

Idarubicin

DRUG

Cytarabine

DRUG

Tretinoin

DRUG

Mitoxantrone

DRUG

Mercaptopurine

DRUG

Methotrexate

Trial Locations (8)

Unknown

French-Belgian-Swiss APL study group, Multiple Locations

AML-CG study group, Multiple Locations

AML-SG study group, Multiple Locations

OSHO study group, Multiple Locations

SAL study group, Multiple Locations

GIMEMA study group, Multiple Locations

HOVON study group, Multiple Locations

PETHEMA study group, Multiple Locations

All Listed Sponsors

collaborator

Gruppo Italiano Malattie EMatologiche dell'Adulto

OTHER

collaborator

Groupe Francophone des Myelodysplasies

OTHER

collaborator

HOVON - Dutch Haemato-Oncology Association

OTHER

collaborator

Programa para el Tratamiento de Hemopatías Malignas

UNKNOWN

collaborator

German Federal Ministry of Education and Research

OTHER_GOV

collaborator

Teva Pharmaceuticals Europe

INDUSTRY

lead

Technische Universität Dresden

OTHER